Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
JW Pharmaceutical Corporation is a South Korean specialty and generic pharmaceutical manufacturer focused on domestic prescription drugs, over-the-counter medications, and contract manufacturing services. The company operates primarily in the Korean market with established distribution relationships across hospitals and retail pharmacies, competing through a diversified portfolio of branded generics and proprietary formulations. Stock performance is driven by domestic healthcare spending trends, regulatory pricing decisions by Korea's National Health Insurance Service, and new product approvals.
JW Pharmaceutical generates revenue through a portfolio approach combining branded generics with higher margins (20-30% gross margins typical for branded generics in Korea) and commodity generics with volume-based economics. Pricing power is constrained by Korea's National Health Insurance reimbursement system which mandates periodic price cuts for established drugs, but the company maintains profitability through continuous new product launches, lifecycle management of existing brands, and operational efficiency in manufacturing. The 12.1% operating margin reflects competitive pressure in generics offset by specialty product mix. Contract manufacturing provides stable cash flow with lower margins but minimal sales/marketing costs.
National Health Insurance Service reimbursement price adjustments - biennial price cuts for established drugs directly impact revenue and margins
New drug approvals from Korea Ministry of Food and Drug Safety - pipeline progression drives growth expectations
Generic drug launch timing and market share capture - first-to-market generic launches can generate 40-60% initial market share
Korean won exchange rate movements - impacts import costs for APIs and raw materials sourced internationally
Domestic pharmaceutical market growth rates - driven by aging demographics and chronic disease prevalence
Government pricing pressure - Korea's National Health Insurance Service implements mandatory price reductions (typically 14-20% cuts every 2 years for established generics) to control healthcare costs amid aging population demographics
Biosimilar and specialty drug competition - global pharmaceutical companies increasingly targeting Korean market with advanced biologics, pressuring traditional small-molecule generic manufacturers
Regulatory approval timelines - Korea MFDS approval processes can extend 18-24 months, delaying revenue recognition from pipeline investments
Domestic competition from larger Korean pharmaceutical companies (Hanmi, Yuhan, Dong-A) with greater R&D budgets and international partnerships
Generic erosion from Chinese and Indian API manufacturers offering lower-cost alternatives, pressuring contract manufacturing margins
Limited international diversification - heavy concentration in Korean market (estimated 85-90% of revenue) creates geographic concentration risk
Elevated capex intensity - $28.1B capex against $79.4B operating cash flow (35% of OCF) suggests significant ongoing facility investments that could pressure free cash flow if revenue growth disappoints
Working capital management - pharmaceutical inventory management requires balancing shelf-life constraints against production efficiency, with potential for write-offs on slow-moving SKUs
low - Pharmaceutical demand is relatively inelastic as prescription drugs address medical needs regardless of economic conditions. However, discretionary OTC product sales show modest correlation with consumer confidence. Korea's universal healthcare system provides stable demand baseline, though government budget constraints during economic downturns can accelerate reimbursement price cuts. The 7.7% revenue growth despite modest economic headwinds demonstrates defensive characteristics.
Low direct sensitivity given minimal debt (0.19 D/E ratio) and strong cash generation ($79.4B operating cash flow). Rising rates have modest negative impact through higher discount rates applied to long-duration drug development investments and potential margin compression if working capital financing costs increase. However, the company's 1.51x current ratio and strong free cash flow ($51.3B) suggest minimal refinancing risk. Valuation multiples (7.7x EV/EBITDA) may compress modestly in rising rate environments as investors rotate toward higher-yielding alternatives.
Minimal - Strong balance sheet with low leverage and positive free cash flow generation reduces dependence on credit markets. Hospital and pharmacy customers in Korea generally maintain stable payment terms backed by National Health Insurance reimbursements, minimizing receivables risk. Tightening credit conditions could indirectly impact through reduced consumer spending on OTC products or delayed hospital capital equipment purchases affecting drug utilization, but effects are secondary.
value - Trading at 1.0x P/S and 7.7x EV/EBITDA with 9.2% FCF yield suggests value orientation. The -3.2% one-year return and negative earnings growth (-5.2% net income, -99.9% EPS) indicate the stock has been out of favor, attracting contrarian value investors betting on stabilization. Strong ROE of 18.4% and ROA of 11.1% demonstrate underlying business quality despite recent headwinds. Limited growth catalysts and mature market position make this more suitable for value investors seeking cash flow generation rather than growth investors.
moderate - Pharmaceutical stocks typically exhibit lower volatility than broader market due to defensive demand characteristics, but Korean small-cap healthcare names can experience elevated volatility from regulatory announcements, reimbursement policy changes, and limited trading liquidity. The -1.5% to -3.2% returns across 3-12 month periods suggest relatively stable but declining price action without major drawdowns.
